IL328751A - Fused ring compound, pharmaceutical composition thereof and use thereof - Google Patents
Fused ring compound, pharmaceutical composition thereof and use thereofInfo
- Publication number
- IL328751A IL328751A IL328751A IL32875126A IL328751A IL 328751 A IL328751 A IL 328751A IL 328751 A IL328751 A IL 328751A IL 32875126 A IL32875126 A IL 32875126A IL 328751 A IL328751 A IL 328751A
- Authority
- IL
- Israel
- Prior art keywords
- pharmaceutical composition
- fused ring
- ring compound
- compound
- fused
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311637621 | 2023-12-01 | ||
| CN202410254237 | 2024-03-06 | ||
| CN202411106833 | 2024-08-13 | ||
| PCT/CN2024/136230 WO2025113714A1 (en) | 2023-12-01 | 2024-12-02 | Fused ring compound, pharmaceutical composition thereof and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL328751A true IL328751A (en) | 2026-07-01 |
Family
ID=95896867
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL328751A IL328751A (en) | 2023-12-01 | 2024-12-02 | Fused ring compound, pharmaceutical composition thereof and use thereof |
Country Status (4)
| Country | Link |
|---|---|
| CN (1) | CN122270458A (en) |
| AU (1) | AU2024389064A1 (en) |
| IL (1) | IL328751A (en) |
| WO (1) | WO2025113714A1 (en) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110753693A (en) * | 2016-12-23 | 2020-02-04 | 阿尔维纳斯运营股份有限公司 | EGFR Proteolytic Targeting Chimeric Molecules and Related Methods of Use |
| US20220143183A1 (en) * | 2019-02-23 | 2022-05-12 | New York University | Photoswitchable protacs and synthesis and uses thereof |
| EP3878472A1 (en) * | 2020-03-12 | 2021-09-15 | Julius-Maximilians-Universitaet Wuerzburg | Proteolysis targeting chimera (protac) for degradation of aurora a-kinase |
| CN113509557A (en) * | 2020-04-09 | 2021-10-19 | 嘉兴优博生物技术有限公司 | Targeted protease degradation platform (TED) |
| CN112062768B (en) * | 2020-07-20 | 2021-08-31 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | Small molecule with Aurora kinase degradation activity and preparation method and application thereof |
-
2024
- 2024-12-02 IL IL328751A patent/IL328751A/en unknown
- 2024-12-02 AU AU2024389064A patent/AU2024389064A1/en active Pending
- 2024-12-02 WO PCT/CN2024/136230 patent/WO2025113714A1/en active Pending
- 2024-12-02 CN CN202480073424.2A patent/CN122270458A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2025113714A1 (en) | 2025-06-05 |
| CN122270458A (en) | 2026-06-23 |
| AU2024389064A1 (en) | 2026-07-16 |